Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years.
Botha S, Fourie CMT, Schutte R, Eugen-Olsen J and Schutte AE
Hypertens Res. 2015 Jun;38(6):439-44. doi: 10.1038/hr.2015.22. Epub 2015 Mar 5.
Shani Botha (South Africa)
1) Summarize your work in one sentence.
In this paper I explored whether the development of hypertension was related to levels of an inflammatory marker, called soluble urokinase plasminogen activator receptor (suPAR), in a black South African population.
2) Summarize your findings in one sentence.
We found that suPAR was higher and increased more prominently in participants who developed hypertension over 5 years than in those who remained normotensive and that becoming hypertensive was associated with an increase in suPAR.
3) Which were the more important methods you used in this work? If it is not a traditional method you can briefly explain the concept of that methodology.
We determined suPAR from plasma EDTA samples with suPARnostic® (ViroGates, Copenhagen, Denmark) ELISA Kits and measured blood pressure with an OMRON HEM-757 device.
4) What did you learn from this paper, what was your take-home message?
These findings highlighted the need for more research on the role of suPAR in hypertension and cardiovascular disease development in black South Africans and may permit the further investigation of the use of suPAR as a potential marker for early risk identification and intervention. Further, whether inflammation leads to the development of hypertension, or vice versa, needs to be established.